Statins and the risk of colorectal cancer

New England Journal of Medicine

Volumn 352, Issue 21, 2005, Pages 2184-2192

  Poynter, Jenny N ^a   Gruber, Stephen B ^a,b   Higgins, Peter D R ^b   Almog, Ronit ^c   Bonner, Joseph D ^b   Rennert, Hedy S ^c   Low, Marcelo ^c   Greenson, Joel K ^b   Rennert, Gad ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; ETHNIC GROUP; FAMILY HISTORY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISRAEL; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SELF REPORT; VEGETABLE; CASE CONTROL STUDY; COLORECTAL TUMOR; DIET; ETHNOLOGY; PEDIGREE; RISK; RISK FACTOR; STATISTICAL MODEL;

AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIET SURVEYS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISRAEL; LOGISTIC MODELS; MALE; PEDIGREE; RISK; RISK FACTORS;

EID: 19444364509     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa043792     Document Type: Article

References (34)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
3. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
4. [Erratum, N Engl J Med 2003;348:1939.]
5. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal antiinflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
6. Rosenberg L, Louik C, Shapiro S. Non-steroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998;82:2326-33.
7. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001;12:88-93.
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
9. Sinensky M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000;1484:93-106.
10. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 1992;339:1154-6.
11. Hentosh P, Yuh SH, Elson CE, Peffley DM. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 2001;32:154-66.
12. Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999;93:1308-18.
13. Rao CV, Newmark HL, Reddy BS. Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detect Prev 2002;26:419-25.
14. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
15. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7.
16. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
17. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
18. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
19. Major outcomes in moderately hyper-cholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
20. The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
22. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-9.
23. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982;36:936-42.
24. Niell BL, Long JC, Rennert G, Gruber SB. Genetic anthropology of the colorectal cancer-susceptibility allele APCI1307K: evidence of genetic drift within the Ashkenazim. Am J Hum Genet 2003;73:1250-60.
25. Bat L, Pines A, Ron E, Rosenblum Y, Niv Y, Shemesh E. Colorectal adenomatous polyps and carcinoma in Ashkenazi and non-Ashkenazi Jews in Israel. Cancer 1986;58:1167-71.
26. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-8.
27. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94.
28. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004;90:635-7.
29. Swamy MV, Cooma I, Reddy BS, Rao CV. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 2002;20:753-9.
30. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999;117;838-47.
31. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341-6.
32. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001;15:211-8.
33. Israel National Cancer Registry, 2005. (Accessed May 2, 2005, at http://www. health.gov.il/icr.)
34. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in observational epidemiology. 2nd ed. New York: Oxford University Press, 1996:239-40.